PATENT—E.D. Va.: USPTO justified in reducing AbbVie’s patent term adjustment by 129 days

The court ruled that the USPTO did not act arbitrarily or exceed its statutory authority under 35 U.S.C. § 154 by applying 37 C.F.R. § 1.704(c)(8) to …